Source for the keratinocyte proliferation hypothesis and the comparison to glucocorticoid-induced skin atrophy
Even with proven outcomes, GLP-1s only reach a fraction of your populationand often cost more than $1,000 per person, per month
We're going to cover how each drug works mechanically (they're not the same), what the head-to-head and independent trial data actually shows, where the side effect profiles differ, and how to figure out which one belongs in your protocol if either does
Retatrutide is a triple agonist, meaning it activates GIP, GLP-1, and glucagon receptors at the same time
This effect of CoQ 10 results in reduced levels of oxidative stress markers such as advanced glycation end products [45] and a decreased rate of inactivation of NO to peroxynitrite by superoxide radicals that could improve vascular tone as well as endothelial function
[15] [1] Metabolic factors: Hypoglycaemia is a consideration , especially in patients with type 2 diabetes taking insulin or sulphonylureas alongside GLP-1 agonists